Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 911 | 168 | 732 |
| Samples | 460 | 108 | 347 |
| Peptides | 357 | 79 | 288 |
Function
INCENP · Inner centromere protein
In mammalian cells, 2 broad groups of centromere-interacting proteins have been described: constitutively binding centromere proteins and 'passenger,' or transiently interacting, proteins (reviewed by Choo, 1997). The constitutive proteins include CENPA (centromere protein A; MIM 117139), CENPB (MIM 117140), CENPC1 (MIM 117141), and CENPD (MIM 117142). The term 'passenger proteins' encompasses a broad collection of proteins that localize to the centromere during specific stages of the cell cycle (Earnshaw and Mackay, 1994 [PubMed 8088460]). These include CENPE (MIM 117143); MCAK (MIM 604538); KID (MIM 603213); cytoplasmic dynein (e.g., MIM 600112); CliPs (e.g., MIM 179838); and CENPF/mitosin (MIM 600236). The inner centromere proteins (INCENPs) (Earnshaw and Cooke, 1991 [PubMed 1860899]), the initial members of the passenger protein group, display a broad localization along chromosomes in the early stages of mitosis but gradually become concentrated at centromeres as the cell cycle progresses into mid-metaphase. During telophase, the proteins are located within the midbody in the intercellular bridge, where they are discarded after cytokinesis (Cutts et al., 1999 [PubMed 10369859]).[supplied by OMIM, Mar 2008].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 345 amino-acid changes on canonical ENST00000394818 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in INCENP · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in INCENP – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 7/40 18% | 0/0 0% |
| Acute Myeloid Leukemia | 7/90 8% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Endometrial Carcinoma | 4/42 10% | 20/612 3% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Non-Small Cell Lung Carcinoma | 17/304 6% | 23/1390 2% |
| Chondrosarcoma | 2/14 14% | 0/75 0% |
| Melanoma | 3/210 1% | 43/1899 2% |
| Colorectal Carcinoma | 13/143 9% | 58/3239 2% |
| Squamous Cell Lung Carcinoma | 7/57 12% | 5/810 1% |
| Cervical Carcinoma | 1/35 3% | 5/422 1% |
| Gastric Carcinoma | 2/74 3% | 22/1809 1% |
| Esophageal Carcinoma | 2/23 9% | 8/769 1% |
| Other Solid Cancers | 1/94 1% | 19/1515 1% |
| Biliary Tract Carcinoma | 1/54 2% | 11/950 1% |
| Thyroid Gland Carcinoma | 3/45 7% | 15/1592 1% |
| Germ Cell Tumour | 1/25 4% | 1/169 1% |
| Bladder Carcinoma | 0/58 0% | 10/956 1% |
| Neuroendocrine Tumour | 4/154 3% | 3/577 1% |
| Osteosarcoma | 2/45 4% | 0/166 0% |
| Other Sarcomas | 1/69 1% | 6/699 1% |
| Mesothelioma | 1/62 2% | 1/165 1% |
| Plasma Cell Myeloma | 2/44 5% | 1/305 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 6/752 1% |
| Ovarian Carcinoma | 4/109 4% | 4/998 0% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Hepatocellular Carcinoma | 1/46 2% | 14/2210 1% |
| Non-Cancerous | 0/104 0% | 6/830 1% |
Mutation Distribution
Where INCENP is mutated · all tissues, split by cell line vs tissue
How many mutations in INCENP were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 911 mutations in INCENP
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|